Ask AI
ProCE Banner Activity

Beamion LUNG-1: Phase I Study of Zongertinib as First-line Treatment for Advanced HER2-Mutant NSCLC

Conference Coverage
Slideset

In the phase Ib Beamion LUNG-1 study, the selective HER2-targeted TKI zongertinib demonstrated an ORR of 77% in patients with previously untreated advanced HER2-mutant NSCLC. 

Released: October 27, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly